← All trials
NCT00526396
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 1, 2007
- Primary completion
- Jan 1, 2016
- Completion date
- Jul 1, 2016
- First posted
- —
- Last posted
- —
- Enrollment
- 160
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- Fondazione Giovanni PascaleLead sponsor
- University of Campania Luigi VanvitelliOverall official - principal investigator
- San Giuseppe Moscati HospitalOverall official - principal investigator
- Giannettasio HospitalOverall official - principal investigator
- Fondazione Giovanni PascaleOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.